Learn how experts recommend using 31-GEP testing to improve melanoma risk assessment, guide sentinel lymph node biopsy decisions, and personalize care.
Read More
Learn how experts recommend using 31-GEP testing to improve melanoma risk assessment, guide sentinel lymph node biopsy decisions, and personalize care.
Read MoreLearn how the 31-gene expression profile test helps predict recurrence, metastasis, and survival in cutaneous melanoma to support personalized risk assessment.
Read MoreExplore key melanoma research from the EADV 2025 Annual Meeting, including surgical margins, genetics, AI, biomarkers, recurrence risk, and treatment advances.
Read MoreExplore key melanoma research from November 2025, including recurrence risk, immunotherapy response, surgery, UV exposure, and quality of life.
Read MoreLearn how 31-GEP testing may better identify melanoma patients who can safely avoid sentinel lymph node biopsy compared with standard staging alone.
Read MoreResults from a prospective multicenter study evaluate whether the integrated 31-gene expression profile test can reduce unnecessary sentinel lymph node biopsies in patients with cutaneous melanoma.
Read More©2026 Oncology Matrix. All Rights Reserved.
